AUTL Autolus Therapeutics ADS

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2023 financial results and operational highlights before open of US markets on Thursday, August 3, 2023.

Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this  to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the of Autolus’ website.

Contact:

Julia Wilson

+44 (0) 7818 430877

Susan A. Noonan

S.A. Noonan Communications



Alexandra Deschner

+ 3



EN
18/07/2023

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and...

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and conditional European marketing authorization from the European Commission (EC) for AUCATZYL®Follow up data from the FELIX trial demonstrating obe-cel's potential for long-term remission in r/r B-ALL presented at the 2025 European Hematology Association (EHA) Co...

18h / 25m 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Report Second Quarter 2025 Financial Results a...

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025. Management will host a conference call and webcast at 8:30am EDT/13:30pm BS...

July 24, 2025 1 EN
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Hoste
EXO EXOR N.V.
AUTL AUTOLUS THERAPEUTICS ADS
AKZA AKZO NOBEL N.V.
ECMPA EUROCOMMERCIAL PROPERTIES NV
07/22/25 July 22, 2025 1 EN
Michiel Declercq
  • Michiel Declercq
AUTL Autolus Therape...

Autolus Aucatzyl gains EC approval in r/r adult ALL

Autolus announced that the European Commission (EC) has granted marketing authorization for Aucatzyl (obe-cel, CD19 CAR-T) for the treatment of adults aged 26+ years with r/r B-ALL. Autolus will now evaluate market entry opportunities in the EU, which we expect to take place on a country-by-country basis – the company has previously indicated that the initial focus in the EU will be on Germany. More broadly, the US commercial launch in r/r adult ALL began in early 2025, and the first quarter of ...

AUTL AUTOLUS THERAPEUTICS ADS
07/22/25 July 22, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel...

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityEC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therape...

July 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch